User login
Key clinical point: G2677T/A and C3435T polymorphisms of multidrug resistance protein 1 (MDR1) play a role in response to imatinib mesylate (IM) in Caucasian population with chronic myeloid leukemia (CML).
Major finding: Variant T/A of G2677 marked responsiveness to IM therapy in Caucasian population under the recessive model (odds ratio [OR], 1.43; P = .01). The 3435TT genotype was significantly associated with increased resistance to IM therapy mainly in Caucasian population under dominant (OR, 1.49; P = .03) and heterozygous (OR, 1.52; P = .04) models.
Study details: Findings are from a meta-analysis of 17 studies involving 4,494 patients with CML; majority were in chronic phase.
Disclosures: The authors did not receive any financial support for research, authorship, and/or publication of this article. The authors declared no potential conflicts of interest.
Source: Louati N et al. J Oncol Pharm Pract. 2021 Feb 10. doi: 10.1177/1078155220981150.
Key clinical point: G2677T/A and C3435T polymorphisms of multidrug resistance protein 1 (MDR1) play a role in response to imatinib mesylate (IM) in Caucasian population with chronic myeloid leukemia (CML).
Major finding: Variant T/A of G2677 marked responsiveness to IM therapy in Caucasian population under the recessive model (odds ratio [OR], 1.43; P = .01). The 3435TT genotype was significantly associated with increased resistance to IM therapy mainly in Caucasian population under dominant (OR, 1.49; P = .03) and heterozygous (OR, 1.52; P = .04) models.
Study details: Findings are from a meta-analysis of 17 studies involving 4,494 patients with CML; majority were in chronic phase.
Disclosures: The authors did not receive any financial support for research, authorship, and/or publication of this article. The authors declared no potential conflicts of interest.
Source: Louati N et al. J Oncol Pharm Pract. 2021 Feb 10. doi: 10.1177/1078155220981150.
Key clinical point: G2677T/A and C3435T polymorphisms of multidrug resistance protein 1 (MDR1) play a role in response to imatinib mesylate (IM) in Caucasian population with chronic myeloid leukemia (CML).
Major finding: Variant T/A of G2677 marked responsiveness to IM therapy in Caucasian population under the recessive model (odds ratio [OR], 1.43; P = .01). The 3435TT genotype was significantly associated with increased resistance to IM therapy mainly in Caucasian population under dominant (OR, 1.49; P = .03) and heterozygous (OR, 1.52; P = .04) models.
Study details: Findings are from a meta-analysis of 17 studies involving 4,494 patients with CML; majority were in chronic phase.
Disclosures: The authors did not receive any financial support for research, authorship, and/or publication of this article. The authors declared no potential conflicts of interest.
Source: Louati N et al. J Oncol Pharm Pract. 2021 Feb 10. doi: 10.1177/1078155220981150.